Modern Pediatrics. Ukraine. 5(109): 45-51. doi 10.15574/SP.2020.109.45
Raitmeyer M. Y., Volosyanko A. B., Synoverska O. B., Ivanyshyn L. Ya., Alekseieva Y. I.
Ivano–Frankivsk National Medical University, Ukraine

For citation: Raitmeyer MY, Volosyanko AB, Synoverska OB, Ivanyshyn LYa, Alekseieva YI. (2020). Debut and course rare of juvenile dermatomyositis. Part II: clinical analysis with comparative analytical review of the literature. Modern Pediatrics. Ukraine. 5(109): 45–51. doi 10.15574/SP.2020.109.45
Article received: Jan 13, 2020. Accepted for publication: May 29, 2020.

The first part of the article describes a rare case of the onset and course of juvenile dermatomyositis. In the second part the comparative clinical analysis of results of own supervision with other similar reports is carried out.
The main attention is focused on atypical variants of the onset of the disease, in particular signs of severe intoxication syndrome, hemorrhagic-necrotic rash, anasarca, lesions of the oral cavity in the form of stomatitis and ulcerative-necrotic glossitis. The difficulties of early diagnosis of the disease on the background of delayed manifestation of pathognomonic skin signs and the absence of reliable features of myopathic syndrome are shown. Clinical and laboratory characteristics of amyopathic juvenile dermatomyositis with persistent skin lesions have been defined. There are three differentiated plans-recommendations of the Childhood Arthritis and Rheumatology Research Alliance for the treatment of patients who have never had muscle damage and those who have had clinical manifestations of myopathy only in the first months of the disease. Current trends in achievements and gaps in the classification, diagnosis and treatment of various forms of juvenile dermatomyositis have been observed. On the basis of scientific publications the possible prognostic consequences of the amyopathic form of this disease in children are highlighted.
The research was carried out in accordance with the principles of the Helsinki Declaration. The study protocol was approved by the Local Ethics Committee of participating institution.
The informed consent of the patient was obtained for conducting the studies.
No conflict of interest was declared by the authors.
Key words: juvenile dermatomyositis, juvenile amyopathic dermatomyositis, atypical course, ulcerative necrotic glossitis, anasarca, psoriasis, treatment.

REFERENCES

1. Bereghnoy VV, German OB. (2016). Myopathic syndromein pediatric cardiorheumatogy, criteria of differential diagnosis (lecture). Sovremennaya pediatriya. 8(80): 84-89. https://doi.org/10.15574/SP.2016.80.84

2. Barsell A, Librizzi J. (2015). A 5-Year-Old Girl with Fatigue, Diffuse Edema, and Weakness. Pediatr Ann. 44(11): 475-476. https://doi.org/10.3928/00904481-20151112-04; PMid:26587813

3. Besnard C, Gitiaux C, Girard M et al. (2019). FRI0309 Severe abdominal manifestations in juvenile dermatomyositis. Annals of the Rheumatic Diseases. 78: 836. https://ard.bmj.com/content/78/Suppl_2/836.1.; https://doi.org/10.1136/annrheumdis-2019-eular.3765

4. Bohan A, Peter JB. (1975). Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 292: 344-347. https://www.nejm.org/doi/full/10.1056/NEJM197502132920706?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpub med; https://doi.org/10.1056/NEJM197502132920706; PMid:1090839

5. Bohan A, Peter JB. (1975). Polymyositis and dermatomyositis (second of two parts), N Engl J Med. 292: 403-407. https://www.nejm.org/doi/full/10.1056/NEJM19750220 2920807?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpub med https://doi.org/10.1056/NEJM197502202920807; PMid:1089199

6. Cao H, Parikh TN, Zheng J. (2009). Amyopathic dermatomyositis or dermatomyositis-like skin disease: retrospective review of 16 cases with amyopathic dermatomyositis. Clin Rheumatol. 28: 979-984. https://doi.org/10.1007/s10067-009-1152-9; PMid:19294477

7. Dourado MR, Filho TJS, Salo T. (2017). Oral signs in juvenile dermatomyositis. J Oral Diag. 2(1). https://doi.org/10.5935/2525-5711.20170027

8. Enders FB, Hofer M. (2011). Juvenile dermatomyositis in Western Switzerland Pediatr Rheumatol. 9(1): 52. https://doi.org/10.1186/1546-0096-9-S1-P52; PMCid:PMC3194711

9. Gerami P, Walling HW, Lewis J et al. (2007). A systematic review of juvenile-onset clinically amyopathic dermatomyositis. BJD. 157(4): 637-644. https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2133.2007.08055.x; https://doi.org/10.1111/j.1365-2133.2007.08055.x; PMid:17596148

10. Gertner E, Rosenbloom MH. (2016). Susac syndrome with prominent dermatological findings and a prompt response to intravenous immunoglobulin, steroids, and rituximab: a case report. J Med Case Reports. 10: 137. https://doi.org/10.1186/s13256-016-0917-4; PMid:27234436 PMCid:PMC4884366

11. Gil B, Merav L, Pnina L et al. (2016). Diagnosis and treatment of clinically amyopathic dermatomyositis (CADM): a case series and literature review. Clin Rheumatol. 35: 2125-2130. https://doi.org/10.1007/s10067-015-2928-8; PMid:25846833

12. Haroon M, Devlin J. (2009). Gottrons's papule in amyopathic dermatomyositis mimicking psoriasis. Clin Rheumatol. 28: 1245-1246. https://doi.org/10.1007/s10067-009-1244-6; PMid:19655085

13. Hoogendijk JE, Amato AA, Lecky BR et al. (2004). 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis. Neuromuscul Disord. 14: 337-345. https://www.nmd-journal.com/article/S0960-8966(04)00040-9/abstract; https://doi.org/10.1016/j.nmd.2004.02.006; PMid:15099594

14. Huber AM, Kim S, Reed AM et al. (2017). The Juvenile Dermatomyositis Research Committee of the Childhood Arthritis and Rheumatology Research Alliance. Childhood Arthritis and Rheumatology Research Alliance Consensus Clinical Treatment Plans for Juvenile Dermatomyositis with Persistent Skin Rash. J Rheumatology. 44(1): 110-116. https://doi.org/10.3899/jrheum.160688; PMid:27803135

15. Ichiyasu H, Sakamoto Y, Yohida C et al. (2017). Rapidly progressive interstitial lung disease in a patient with anti-MDA5-positive amyopathic dermatomyositis. Respiratory Medicine Case Report. 20: 51-54. https://journals.lww.com/jpho-online/Abstract/2010/04000/JuvenileDermatomyositis-as-a-Paraneoplastic.4.aspx; https://doi.org/10.1016/j.rmcr.2016.11.015; PMid:27995057 PMCid:PMC5153447

16. Kim NN, Lio PA, Morgan GA et al. (2011). Double Trouble: Therapeutic Challenges in Patients With Both Juvenile Dermatomyositis and Psoriasis. Arch Dermatol. 147(7): 831-835. https://doi.org/10.1001/archdermatol.2011.49; PMid:21422326

17. Kim S, Kahn P, Robinson AB et al. (2017). Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease. Pediatr Rheumatol. 15(1). https://doi.org/10.1186/s12969-016-0134-0; PMid:28077146 PMCid:PMC5225591

18. Leman J, Burden D. (2001). Psoriasis in Children. Paediatr Drugs. 3: 673-680. https://doi.org/10.2165/00128072-200103090-00005; PMid:11688598

19. Lundberg IE, Tjarnlund A, Bottai M et al. (2017). European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 76(12): 1955-1964.

20. McCann LJ, Juggins AD, Maillard SM et al. (2006). The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland) – clinical characteristics of children recruited within the first 5-yr. Rheumatology. 45(10): 1255-1260. https://doi.org/10.1093/rheumatology/kel099; PMid:16567354

21. Mamyrova G, Kishi T, Targoff IN et al. (2018). Childhood Myositis Heterogeneity Collaborative Study Group, Features distinguishing clinically amyopathic juvenile dermatomyositis from juvenile dermatomyositis. Rheumatology. 57(11): 1956-1963. https://academic.oup.com/rheumatology/article/57/11/1956/5054648; https://doi.org/10.1093/rheumatology/key190; PMid:30016492 PMCid:PMC6199536

22. Maritsi D, Leahy CA. (2010). Juvenile dermatomyositis with tongue calcinosis and poor growth. Arch Dis Child. 95(12): 997. https://adc.bmj.com/content/95/12/997.citation-tools; https://doi.org/10.1136/adc.2010.188318; PMid:21030377

23. Markovic A, Schuster V, Simon J-C, Kunz M. (2019). Erythematous scaling lesions of the face, dorsal fingers, elbows, and knees together with symmetrical muscle weakness in a child. Clin Case Reports. 7(7): 1347-1349. https://doi.org/10.1002/ccr3.2219; PMid:31360483 PMCid:PMC6637353

24. Mentery A, Cordoro KM, Davis DMR et al. (2020). Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. JAAD. 82(1): 161-201. https://doi.org/10.1016/j.jaad.2019.08.049; PMid:31703821

25. Mitchell JP, Dennis GJ, Rider LG. (2001). Juvenile dermatomyositis presenting with anasarca: A possible indicator of severe disease activity. J Pediatr. 138(6): 942-945. https://doi.org/10.1067/mpd.2001.113363; PMid:11391348

26. Montoya CL, Gonzalez ML, Ospina FE et al. (2017). A Rare Case of Amyopathic Juvenile Dermatomyositis Associated With Psoriasis Successfully Treated With Ustekinumab. JCR: Journal of Clinical Rheumatology. 23(2): 129-130. https://doi.org/10.1097/RHU.0000000000000430; PMid:28099216

27. Nandy A, Ga?ni S, Sore P. (2018). Rapidly progressive interstitial lung disease in a patient with anti-MDA5-positive amyopathic dermatomyositis. Scand J Rheum. 47(4): 334-335. https://www.tandfonline.com/doi/cited-by/10.1080/03009742.2017.1369155?scroll=top&needAccess=true; https://doi.org/10.1080/03009742.2017.1369155; PMid:29043891

28. Okong'o LO, Esse M, Wilmshurst J et al. (2016). Characteristics and outcome of children with juvenile dermatomyositis in Cape Town: a cross-sectional study. Pediatr Rheumatol Online J. 14(1): 60. https://doi.org/10.1186/s12969-016-0118-0; PMid:27835954 PMCid:PMC5106783

29. Pearson CM. (1979). Polymyositis and dermatomyositis. In: Arthritis and Allied Conditions (McCarty DJ, ed.), 9th edn. Philadelphia: Lea and Febiger: 742-761.

30. Peloro TM, O.Fred Miller OF, Thomas F, Hahn TF, Eric D. Newman ED. (2001). Juvenile dermatomyositis: A retrospective review of a 30-year experience. JAAD. 45(1): 28-34. https://doi.org/10.1067/mjd.2001.113686; PMid:11423831

31. Ravelli A, Trail L, Ferrari C et al. (2010). Long-term outcome and prognostic factors of juvenile dermatomyositis: A multinational, multicenter study of 490 patients. Arthritis Care Res. 62(1): 63-72. https://doi.org/10.1002/acr.20015; PMid:20191492

32. Rider LG, Nistala K. (2016). The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes. Journal of internal medicine. 280(1): 24-38. https://doi.org/10.1111/joim.12444; PMid:27028907 PMCid:PMC4914449

33. Robazzi TCMV, Bulhoes C, Chaves L et al. (2017). A case of severe cutaneous involvement on initial clinical presentation of juvenile dermatomyositis. Rev Argent Reum. 28(3): 33-37. http://revistasar.org.ar/revistas/2017/n3/6_caso_clinico.pdf.

34. Robinson AB, Hoeltzel MF, Wahezi DMet et al. (2014). Clinical Characteristics of Children With Juvenile Dermatomyositis: The Childhood Arthritis and Rheumatology Research Alliance Registry. Arthr Res. (66): 404-410. https://doi.org/10.1002/acr.22142; PMid:23983017 PMCid:PMC4078654

35. Ruparelia P, Verma O, Shah V, Shah K. (2018). Juvenile dermatomyositis – a case report with review on oral manifestations and oral health considerations. Intational Journal of Orofacial Myology. 44: 52-61. https://web.a.ebscohost.com/abstract?direct=true&profile=ehost&scope=site&authtype=crawler&jrnl=07350120&AN=142035268&h=lc0YUyjo2zowwIqIRAPrzH2xvCmlagfd9YvhvfEUlnT6DjBOYzBl7JluaeY6wsmLpxonQcgk842CY6g80PZV9g%3d%3d&crl=c&resultNs=AdminWebAuth&resultLocal=ErrCrlNotAuth&crlhashurl=login.aspx%3fdirect%3dtrue%26profile%3dehost%26scope%3dsite%26authtype%3dcrawler%26jrnl%3d07350120%26AN%3d142035268.

36. Pavlović MD, Zečević RD, Zolotarevski L. (2004). Psoriasis in patients with dermatomyositis. Military Medical Review. 61(5): 557-559. https://doi.org/10.2298/VSP0405557P; PMid:15551809

37. Sanner H, Gran J-T, Sjaastad I et al. (2009). Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset. Rheumatology. 48(12): 1541-1547. https://academic.oup.com/rheumatology/article/48/12/1541/1787359; https://doi.org/10.1093/rheumatology/kep302; PMid:19776224

38. Saygi S, Alehan F, Baskin E et al. (2008) Juvenile Dermatomyositis Presenting With Anasarca. Journal Child Neur. 23(11): 1353-1356. https://doi.org/10.1177/0883073808318544; PMid:18984850

39. Schwartz T, Sanner H, Gjesdal O et al. (2014). In juvenile dermatomyositis, cardiac systolic dysfunction is present after long-term follow-up and is predicted by sustained early skin activity. Ann Rheumatic Diseases. 73: 1805-1810. https://doi.org/10.1136/annrheumdis-2013-203279; PMid:23881732

40. Stringer E, Bohnsack J, Bowyer SL et al. (2010). Treatment Approaches to Juvenile Dermatomyositis (JDM) Across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey. J Rheumatology. 37(9): 1953-1961. https://doi.org/10.3899/jrheum.090953; PMid:20595275

41. Sugimori Y, Yamashita H, Yorifuji H et al. (2018). A Case of Clinically Amyopathic Dermatomyositis With Hoarseness Due to Vocal Cord Necrosis. Journal of Clinical Rheumatology. 24(1): 50-51. https://journals.lww.com/jclinrheum/Citation/2018/01000/A_Case_of_Clinically_Amyopathic_Dermatomyositis.13.aspx?sessionEnd=true; https://doi.org/10.1097/RHU.0000000000000575; PMid:29239926

42. Tansley SL, Betteridge ZE, Gunawardena H et al. (2014). Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. Arthritis Res Ther. 16: R138. https://doi.org/10.1186/ar4600; PMid:24989778 PMCid:PMC4227127

43. Vardeh H, Magro CM, Cynthia M et al. (2016). Gastrointestinal Pathology Associated With Dermatomyositis: Presentation of 3 Cases and a General Review. A.J.S.P.: Rev. & Rep. 21: 293-300. https://journals.lww.com/pathologycasereviews/Abstract/2016/11000/Gastrointestinal_Pathology_Associated_With.8.aspx.

44. Walling HW, Gerami P, Sontheimer RD. (2010). Juvenile-Onset Clinically Amyopathic Dermatomyositis. Pediatr-Drugs. 12: 23-34. https://doi.org/10.2165/10899380-000000000-00000; PMid:20034339

45. Xing Y, Xie J, Jiang S et al. (2019). Co-existence of Juvenile dermatomyositis and psoriasis vulgaris with fungal infection: A case report and literature review. JCD. 18(5): 1560-1563. https://doi.org/10.1111/jocd.12869; PMid:30697901

46. Zedan M, El-Ayouty M, Abdel-Hady H et al. (2008). Anasarca: not a nephrotic syndrome but dermatomyositis. J Pediatr. 167(7): 831-834. https://doi.org/10.1007/s00431-008-0716-z; PMid:18414893